The trajectory of companies tied to Viagra's history presents a complex investment landscape. While the initial success generated substantial gains, generic alternatives have significantly eroded market share . Investing in associated pharmaceutical businesses now requires a careful assessment of patent safeguards, evolving healthcare trends , and